Testosterone deficiency syndrome (TDS) is a clinical and biochemical entity related to sexual and cardiovascular health. Hypertension, diabetes mellitus (DM), dyslipidemia and overweight are four clinical factors strongly related to cardiovascular illnesses. The aim of our study was to determine if the presence and number of cardiovascular risk factors was related to total testosterone levels and the presence of biochemical TDS. We retrospectively analyzed 384 patients referred to our center for prostate biopsy between September 2007 and December 2009. Variables age, height, weight, body mass index (BMI), tobacco use, alcohol intake, hypertension, DM, dyslipidemia (hypercholesterolemia/hypertriglyceridemia) and overweight (BMI425) were recorded prospectively. Hormonal profile was determined as part of our clinical protocol. We used 231 and 346 ng dl À1 as total testosterone cut-points (8 --12 nmol l À1 ) for diagnosis of biochemical TDS, following ISA-ISSAM-EAU Guidelines. We analyzed the relationship between testosterone levels and the presence of hypertension, DM, dyslipidemia and overweight, and with the number of these cardiovascular risk factors. Mean age was 66±8 years. Prevalence of TDS was 6.5% within the 231 ng ml À1 cutoff point and 28.4% for the 346 ng dl À1 cutoff point. Levels of testosterone were related to hypertension (P ¼ 0.007), dyslipidemia (P ¼ 0.013), overweight (P ¼ 0.036) and the number of cardiovascular risk factors (P ¼ 0.018). The prevalence of TDS in our population is comparable to data from international studies. Testosterone levels decrease as the number of cardiovascular risk factors rise.
INTRODUCTION
Testosterone deficiency syndrome (TDS) is an entity of growing concern. Previous literature indicates that TDS affects up to 10% 1, 2 of population over 50 years old and its prevalence increases up to 30% in males above 80 years old. 3 TDS is defined by both clinical and biochemical criteria. 4 From a clinical point of view, the symptoms defining testosterone deficiency are indistinguishable from physiological process of ageing like loss of libido, erectile dysfunction, decreased muscle mass and strength, increased body fat, decreased bone mineral density and osteoporosis, and decreased vitality and depressed mood. 4 Testosterone is closely related to erectile function and sexual drive. Consequently, testosterone determination is mandatory in the differential diagnosis of male impotence. 5 Testosterone level is related to other entities not related with the sexual sphere such as diabetes mellitus (DM), 6 metabolic syndrome (MS), 7 heart disease 8 and even mortality. 9 MS is a cluster of risk factors that includes abdominal obesity, increased blood fasting glucose, dyslipidemia and hypertension. 10 Individuals diagnosed with MS have five times the risk of developing DM type 2 and a twofold increase in cardiovascular disease at 5 to 10 years, respectively. 11 In a complete different clinical setting, males undergoing androgenic deprivation therapy for prostate cancer have a greater risk of developing MS. 12 Thus, hypertension, DM, dyslipidemia and overweight/obesity are clinical entities with a deep impact in cardiovascular health that raises the risk of developing coronary artery disease.
Currently, population screening for TDS is not advised and no questionnaire has demonstrated effective in proving the existence of TDS or predicting its diagnosis. 4 Thus, the only means of diagnosing TDS is through a testosterone determination after a clinical suspicion of TDS. Therefore, we sought to identify clinical risk factors for TDS, which may be used to identify individuals at high risk for developing TDS, and suitable for screening.
We chose prostate biopsy men to analyze the interaction between hormonal pattern and hypertension, diabetes, dyslipidemia and overweight, all these cardiovascular risk factors, as plenty of data on hormonal pattern and clinical variables was available. The aim of the study was to support the contention that testosterone levels are lower in men with hypertension, diabetes, dyslipidemia and overweight, and that the addition of these cardiovascular risk factors induces an additive effect in the descent of T levels.
MATERIALS AND METHODS
We retrospectively analyzed 384 men who received a transrectal ultrasound-guided prostate biopsy performed in our center between September 2007 and December 2009. We retrospectively recorded age, body mass index (BMI), smoking and drinking habits, hypertension, DM/ glucose intolerance and dyslipidemia (hypercholesterolemia/hypertriglyceridemia).
The indication for prostate biopsy was suspicion of prostate cancer based on the results of digital rectal examination and/or elevations of serum prostate-specific antigen. Screening was carried out with 5 þ 5 cores transrectal ultrasound-guided prostate biopsy. As part of our clinical protocol, we determined hormonal patterns (testosterone and sex hormone-binding globulin (SHBG) using an automated immunometric chemiluminescent method (Cobas Roche, West Sussex, UK)) in these patients. Serum samples were collected by venipuncture of fasting patients between 0700 --1100 hours. Patients who were receiving luteinizing hormone-releasing hormone analogues or testosterone replacement therapy were excluded from the analysis.
Following ISA-ISSAM-EAU Guidelines recommendations, 4 À2 . The number of cardiovascular risk factors was worked out by adding hypertension (yes/no), DM (yes/no), dyslipidemia (yes/no) and overweight (yes/no).
Statistical analysis
We used both analysis of variance to assess the univariate association between number of cardiovascular risk factors present and continuous measures (testosterone, SHBG, age and BMI). Using linear regression, we modeled the multivariate adjusted associations between testosterone and SHBG. Tobacco, hypertension, DM and dyslipidemia were analyzed as categorical variables (tobacco; non-smoker, smoker and former smoker), whereas cumulative tobacco use and daily alcohol intake dose were examined as continuous variables and overweight was analyzed as a dichotomous variable (BMI o25 vs X25). Last of all, we analyzed the relationship between testosterone and the number of factors of cardiovascular risk (categorical variable).
In the population study, we analyzed if there was any relationship between hormonal pattern and cardiovascular risk factors (hypertension, DM, dyslipidemia and overweight) and the number of factors of cardiovascular risk.
RESULTS
Clinical and biochemical data of the 384 patients are shown in Table 1 .
The outcomes of the univariate analysis between clinical and hormonal variables are displayed in Table 2 .
We found that total testosterone levels were associated with hypertension (no hypertension 465 ± 175 ng dl À1 vs hypertension 417±142 ng dl À1 , P ¼ 0.007), dyslipidemia (no dyslipidemia 459±168 ng dl À1 vs dyslipidemia 407±149 ng dl À1 , P ¼ 0.013) and overweight (no overweight 470 ± 168 ng dl À1 vs overweight 424 ± 154 ng dl À1 , P ¼ 0.036). In addition, we found that total testosterone levels were inversely related to the number of cardiovascular risk factors (0 factors: 492±171 ng dl À1 ; 1 factor: 453 ± 169 ng dl À1 ; 2 factors: 411 ± 142 ng dl À1 ; 3 factors: 399 ± 135 ng dl À1 , P ¼ 0.018), as shown in Figure 1 . With regard to SHBG, overweight men were found to have lower levels of SHBG (54.6 ± 27.5 vs 45 ± 22.2; P ¼ 0.004), as shown in Table 2 .
The analysis among independent variables and the rate of hypogonadism (testosterone o231 and testosterone o346 ng dl
À1
) is shown in Table 3 . Males with dyslipidemia tend to have higher rates of testosterone o346 ng dl À1 (25.9 vs 37.2%; P ¼ 0.048). Of note that, although it did not reach statistical significance, the rate of TDS (both cutoff points) increased as the number of cardiovascular risk factors increased.
DISCUSSION
Testosterone is a closely related hormone with MS, 13 which is one of the most worrying problems threatening the health of societies in the developed countries.
14 Moreover, TDS has been related not only to MS but also to other important health issues, such as heart disease and even mortality. 6 --10 In a similar manner, hypertension, DM, dyslipidemia and overweight/obesity are considered to be some of the most important risk factors to develop coronary artery disease.
Although our data were derived from a convenience sample of men suspicious for prostate cancer, our findings are consistent with other Spanish population data on the prevalence of TDS, although the sample does not proceed from general population. Our data show that up to 8% of men are affected by biochemical hypogonadism using the 8-nmol l À1 cutoff, or up to 28% using a less restrictive level of 12 nmol l À1 . Martínez-Jabaloyas 15 reported a TDS prevalence of 33% in a cohort of 1340 Spanish men using a cutoff of 12 nmol l
À1
. In this same population, lower testosterone patients were more likely to suffer hypertension, DM, dyslipidemia and overweight. Our study supports the claim that testosterone levels are closely related to the most common cardiovascular and metabolic diseases. 6, 7, 10 Furthermore, our data show an additive impact of the number of cardiovascular risk factors, lowering testosterone levels as number of factors raises, as published earlier by Kaplan. 16 Similarly, in a meta-analysis yet to be published, 10 it was concluded that patients with MS showed lower testosterone levels than healthy individuals. In this meta-regression, differences in testosterone were higher in studies comparing males with and without MS in cohorts affected by high rates of DM.
Testosterone levels positively correlate with insulin sensitivity, 10 independently of body composition, 17 whereas testosterone decrease (as in androgen deprivation in prostate cancer patients 12 ) is related to impaired insulin sensitivity. Insulin itself is able to stimulate testosterone production and inhibit SHBG production; 18, 19 however, our data do not support this correlation. In our opinion, selection bias in our population might explain this lack of relationship. 
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Regarding testosterone and cholesterol levels, testosterone supplementation is generally believed to affect high-density lipoprotein cholesterol without any impact in total cholesterol levels. 19 Although a meta-analytic review failed to find testosterone effect on cholesterol levels, it has been pointed out a possible confounder effect of statins or the short follow-up in most trials analyzing this relationship. 20 In this regard, our data support the conceptual principle that one of the bases of MS, dyslipidemia, is inversely related to testosterone levels. Nevertheless, we did not record statin use and this should be taken into consideration when analyzing our data.
The relationship between hypertension and testosterone is a matter of debate. On one hand, several groups have found that patients with hypertension have lower testosterone levels, 21 whereas other studies have failed to find this relationship. 22 Our data show an inverse relationship between hypertension and testosterone levels, reinforcing the concept that MS is a cluster of ailments related among each other. 6 --8,10,13 Overweight, especially measured using waist circumference, has been proved to be a risk factor for low testosterone levels. 20 Although we did not measure waist circumference, we used a surrogate marker for central obesity such as BMI. Using this determination, our patients with over 25 kg m À2 had lower testosterone levels, confirming the idea that overweight has a crucial role as a cardiovascular risk factor and in testosterone deficiency.
Some limitations in our study must be considered. First, our study is a retrospective analysis of a cohort of males undergoing prostate biopsy in a single center. The fact that this cohort is not general population is reflected by the rates of hypertension, DM, dyslipidemia and obesity in our population being much higher than the rates of these entities published in Spanish general population. As commented above, this selection bias might be the reason why we did not find any relationship between hormonal pattern and age or DM. Second, we did not record data on TDS symptoms, and as such, we cannot address the possible clinical aspects of the effect of lower testosterone values in our population or the possible positive bias of patients consulting their primary care physicians with TDS symptoms. Third, the use of a cross-sectional study does not take into consideration that TDS and cardiovascular disease are part of dynamic processes, developing over many years.
In conclusion, the number of cardiovascular risk factors is inversely related to testosterone levels. From our understanding, this fact can be analyzed in two ways. First, a deeper alteration in metabolism leads to a lowering in testosterone levels. Second, an abnormal level of testosterone might be related with the development of some aspects of cardiovascular risk such as hypertension, DM, dyslipidemia and obesity/overweight. 10 From a clinical point of view, our data show that defining a population at risk for TDS is feasible. Considering that TDS is a frequent entity that has shown negative impact in life expectancy, with an easy diagnosis and an effective treatment, all these characteristics make TDS suitable for population screening. Nonetheless, Lower testosterone levels E Garcia-Cruz et al a multi-center trial should be considered to validate our data and define males at risk of suffering TDS. Abbreviation: TDS, testosterone deficiency syndrome. w 2 test was used when both variables were categorical. Student's t-test was used when one variable was categorical and the other was continuous. In the columns, first value represents data of males with testosterone levels above cutoff while the second value represents data of males below cutoff. No clinical variable was related to the presence of biochemical hypogonadism irrespectively of testosterone cutoff points considered (231 and 346 ng dl À1 ).
